{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.2","upperLimit":"76.9","value":"56.3"},{"groupId":"OG001","lowerLimit":"35.4","upperLimit":"87.9","value":"66.7"},{"groupId":"OG002","lowerLimit":"5.8","upperLimit":"39.2","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"Percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) as determined by the investigators. CR = disappearance of all target lesions. PR = greater than equal to (\\>=) 30% decrease in sum of target lesions taking as reference baseline sum diameters. ORR based on Cheson criteria was defined similarly however, confirmation of response was not required. If participant had tumor response assessed only by RECIST or Cheson, then ORR was based on the single result. If tumor response was assessed by both RECIST and Cheson, then ORR was reported based on tumor response by Cheson criteria unless the Cheson has indeterminate result, in which case the RECIST result was reported. Participant(s) who did not have tumor assessment results from either RECIST 1.1 or Cheson criteria reported at baseline were to be excluded from the analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"In ALK genetic event positive participants with ALCL, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG000","title":"ALCL Arm"},{"description":"In ALK genetic event positive participants with IMT, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG001","title":"IMT Arm"},{"description":"In ALK genetic event positive participants with other tumors (excluding non-small cell lung cancer), crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"OG002","title":"Other Tumors"}],"paramType":"NUMBER","populationDescription":"All participants who were enrolled and received at least 1 dose of study treatment, and had adequate baseline tumor assessment by either RECIST 1.1 or Cheson criteria.","reportingStatus":"POSTED","timeFrame":"From the date of first dose of study medication to the date of the first documentation of objective tumor progression or death on treatment due to any cause, whichever occured first (maximum 374 weeks)","title":"Objective Response Rate (ORR) - Percentage of Participants With Objective Response","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}